ATE494903T1 - Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden - Google Patents

Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden

Info

Publication number
ATE494903T1
ATE494903T1 AT04727963T AT04727963T ATE494903T1 AT E494903 T1 ATE494903 T1 AT E494903T1 AT 04727963 T AT04727963 T AT 04727963T AT 04727963 T AT04727963 T AT 04727963T AT E494903 T1 ATE494903 T1 AT E494903T1
Authority
AT
Austria
Prior art keywords
slurp
acetylcholine receptor
diseases caused
treat diseases
methods
Prior art date
Application number
AT04727963T
Other languages
English (en)
Inventor
Fabrice Chimienti
Ronald Hogg
Marcel Huber
Daniel Bertrand
D Hohl
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE494903T1 publication Critical patent/ATE494903T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
AT04727963T 2003-04-16 2004-04-16 Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden ATE494903T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46341803P 2003-04-16 2003-04-16
PCT/IB2004/001716 WO2004091646A2 (en) 2003-04-16 2004-04-16 Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction

Publications (1)

Publication Number Publication Date
ATE494903T1 true ATE494903T1 (de) 2011-01-15

Family

ID=33300074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727963T ATE494903T1 (de) 2003-04-16 2004-04-16 Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden

Country Status (11)

Country Link
US (2) US7135454B2 (de)
EP (1) EP1613341B1 (de)
JP (1) JP4891065B2 (de)
AT (1) ATE494903T1 (de)
AU (1) AU2004229237B2 (de)
CA (1) CA2520029C (de)
DE (1) DE602004031003D1 (de)
ES (1) ES2359408T3 (de)
IL (1) IL171384A (de)
NO (1) NO337494B1 (de)
WO (1) WO2004091646A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786473A4 (de) * 2004-08-11 2008-11-19 Cedars Sinai Medical Center Behandlung von parkinson-krankheit und verwandter erkrankungen
US7858590B2 (en) * 2005-08-11 2010-12-28 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
US20080221013A1 (en) * 2006-09-02 2008-09-11 Julie Miwa Neurobiological compositions
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
RU2453602C2 (ru) * 2010-08-19 2012-06-20 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pЕТ22b(+)/SLURP-1, КОДИРУЮЩАЯ БЕЛОК SLURP-1, И ШТАММ БАКТЕРИЙ Escherichia coli BL21(DE3)/pET22b(+)/SLURP-1-ПРОДУЦЕНТ БЕЛКА SLURP-1 ЧЕЛОВЕКА
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
JP6144673B2 (ja) 2011-06-03 2017-06-07 オフィディオン インコーポレイティド 血液脳関門を通過して輸送するための組成物及び方法
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
EP2740485B1 (de) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 zur verwendung bei der behandlung von augenkrankheiten
CN114601915B (zh) * 2022-03-25 2023-04-07 四川大学华西医院 Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5298604A (en) 1992-07-27 1994-03-29 Sloane Nathan H Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes
IT1257184B (it) * 1992-12-22 1996-01-10 Applied Research Systems Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale
ATE234110T1 (de) 1996-04-24 2003-03-15 Applied Research Systems Komponente b als wundheilendes mittel
WO1998056810A2 (de) * 1997-06-09 1998-12-17 Forssmann Wolf Georg Humanes protein lus-i, seine herstellung und verwendung
JP2002520292A (ja) 1998-07-09 2002-07-09 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ ヒト成長因子と組み合わせた血管形成剤としてのコンパウンドｂの使用

Also Published As

Publication number Publication date
NO20055309D0 (no) 2005-11-10
WO2004091646A3 (en) 2004-12-16
US7691808B2 (en) 2010-04-06
US20050004025A1 (en) 2005-01-06
NO337494B1 (no) 2016-04-25
CA2520029A1 (en) 2004-10-28
EP1613341A2 (de) 2006-01-11
DE602004031003D1 (de) 2011-02-24
JP2006523678A (ja) 2006-10-19
ES2359408T3 (es) 2011-05-23
US7135454B2 (en) 2006-11-14
JP4891065B2 (ja) 2012-03-07
AU2004229237B2 (en) 2009-06-04
IL171384A (en) 2010-12-30
NO20055309L (no) 2006-01-16
EP1613341B1 (de) 2011-01-12
AU2004229237A1 (en) 2004-10-28
WO2004091646A2 (en) 2004-10-28
CA2520029C (en) 2014-07-15
US20070219130A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
GB0222495D0 (en) Compounds
DE602005019874D1 (de) Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
TW200611695A (en) Pyrrolopyridine derivatives
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
TW200735868A (en) Compositions and methods for treating CNS disorders
DE60023139D1 (de) Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties